| Literature DB >> 35055982 |
Paula Santibáñez1, Concepción García-García1, Aránzazu Portillo1, Sonia Santibáñez1, Lara García-Álvarez1, María de Toro2, José A Oteo1.
Abstract
Infective endocarditis (IE) is a severe and life-threatening disease. Identification of infectious etiology is essential for establishing the appropriate antimicrobial treatment and decreasing mortality. The aim of this study was to explore the potential utility of metataxonomics for improving microbiological diagnosis of IE. Here, next-generation sequencing (NGS) of the V3-V4 region of the 16S rRNA gene was performed in 27 heart valve tissues (18 natives, 5 intravascular devices, and 4 prosthetics) from 27 patients diagnosed with IE (4 of them with negative blood cultures). Metataxonomics matched with conventional diagnostic techniques in 24/27 cases (88.9%). The same bacterial family was assigned to 24 cases; the same genus, to 23 cases; and the same species, to 13 cases. In 22 of them, the etiological agent was represented by percentages > 99% of the reads and in two cases, by ~70%. Staphylococcus aureus was detected in a previously microbiological undiagnosed patient. Thus, microbiological diagnosis with 16S rRNA gene targeted-NGS was possible in one more sample than using traditional techniques. The remaining two patients showed no coincidence between traditional and 16S rRNA gene-targeted NGS microbiological diagnoses. In addition, 16S rRNA gene-targeted NGS allowed us to suggest coinfections that were supported by clinical data in one patient, and minority records also verified mixed infections in three cases. In our series, metataxonomics was valid for the identification of the causative agents, although more studies are needed before implementation of 16S rRNA gene-targeted NGS for the diagnosis of IE.Entities:
Keywords: 16S rRNA gene; NGS; Spain; heart valves; infective endocarditis; metataxonomy
Year: 2021 PMID: 35055982 PMCID: PMC8781873 DOI: 10.3390/pathogens11010034
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Contributions of 16S rRNA gene-targeted NGS from heart valve tissue specimens to the diagnosis of infective endocarditis for the 27 patients of this study.
| Patient ID | Initial Microbiological Diagnosis | Identification Technique(s) | Bacterial Taxa with the Highest Relative Abundance and | |
|---|---|---|---|---|
| High confident | #1 |
| PCR, WEC 1 | |
| #2 |
| BC, PCR | ||
| #3 |
| BC, PCR | ||
| #4 | BC, PCR | |||
| #5 | BC, PCR | |||
| #6 |
| BC | ||
| #7 |
| BC, PCR | ||
| #8 |
| BC, PCR | ||
| #9 |
| BC, PCR | ||
| #10 |
| BC, PCR | ||
| #11 |
| PCR | ||
| #12 |
| BC, PCR | ||
| #13 |
| BC, PCR | ||
| #14 |
| BC, PCR | ||
| #15 |
| BC, PCR | ||
| #16 |
| BC, PCR | ||
| #17 |
| BC, PCR | ||
| #18 | BC 2, PCR 3 | |||
| Corroborated mixed | #19 |
| BC, PCR, IFA 4, | |
| #20 |
| BC, PCR, CTC 5 | ||
| #21 |
| BC, PCR, VC 6, BC 7† | ||
| Reclassified as | #22 |
| PCR | |
| Low confident | #23 |
| BC, PCR | |
| #24 |
| BC, PCR | ||
| New diagnosis | #25 | No etiology | BC, PCR | |
| Discordant diagnosis | #26 |
| BC, PCR | |
| #27 |
| BC |
ID, identification number; 1, 2, 3, 4, 5, 6 and 7, technique by which the microorganism was detected; PCR, polymerase chain reaction (targeting 16S rRNA gene from heart valve tissues); WEC, wound exudate culture; BC, blood culture; IFA, immunofluorescence assay; htpAB PCR, PCR targeting the htpAB gene for C. burnetii; CTC, catheter tip culture; VC, heart valve culture; †, after surgery. *, a total of 11 bacterial taxa were detected at relative abundance > 1% (See Supplementary Table S1).
Main advantages and disadvantages of classic techniques and 16S rRNA gene-targeted NGS for the microbiological diagnosis of infected endocarditis.
| Technique | Advantages | Disadvantages |
|---|---|---|
| Blood culture | Cornerstone of diagnosis | Limited sensitivity, especially after antibiotic therapy or for fastidious |
| PCR | More sensitive and faster than culture | Variable sensitivity (blood vs. valve; 16S rRNA gene vs. specific targets) |
| Valve culture | Definitive diagnosis | Low specificity (tedious handling of sample) |
| Serology | Particularly useful in BCNE caused by | Low sensitivity and specificity |
| 16S rRNA gene-targeted NGS | High-throughput sequencing | Variable sensitivity (targeted region, bioinformatics |
MALDI-TOF, matrix-assisted laser desorption/ionization-time-of-flight; PCR, polymerase chain reaction; BCNE, blood culture-negative endocarditis; NGS, next-generation sequencing.
Main epidemiological and clinical characteristics of the 27 patients.
| ID | Year of | Age, Sex | Affected | IE | Cardiac | Most | Charlson | Vegetation | Fever | Embolisms | Heart Murmur | Vascular Phenomena | Intracardiac Complications | Cardiac Failure | Antibiotic Therapy (Days) ^ | Mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 2012 | 56, F | ivd | P | CD, AVB, | - | 2 | N | Y | N | N | N | N | N | 1 | N |
| #2 | 2013 | 69, M | pav | P | CD, AS, MI, HS | - | 3 | Y | Y | N | Y | N | Y | N | 6 | UN |
| #3 | 2017 | 67, M | nav | D | CD, AI, AF | ARF | 4 | Y | N | N | N | N | Y | Y | 11 | N |
| #4 | 2011 | 64, M | ivd | D | CD, HF, DM, AF | LD | 8 | Y | Y | N | N | N | N | N | 48 | N |
| #5 | 2012 | 71, F | nav | D | - | - | 3 | Y | Y | N | Y | N | N | Y | 6 | Y |
| #6 | 2014 | 68, F | pmv | D | AF, TI, NVD | n-aHC | 7 | Y | Y | N | N | N | Y | N | 18 | Y |
| #7 | 2016 | 53, M | nav | D | - | - | 1 | Y | Y | N | Y | N | Y | N | 8 | N |
| #8 | 2016 | 54, F | nmv | D | - | HP | 1 | Y | Y | N | Y | N | N | N | 22 | N |
| #9 | 2016 | 53, M | nmv | D | CD | CLD | 2 | Y | N | Y | Y | N | N | N | 18 | N |
| #10 | 2017 | 45, M | nmv | D | - | - | 0 | Y | Y | N | Y | N | N | N | 13 | N |
| #11 | 2011 | UN, F | ivd | UN | UN | UN | UN | UN | UN | UN | UN | UN | UN | UN | UN | UN |
| #12 | 2015 | 69, F | nmv | D | - | GBS | 3 | Y | Y | Y | N | Y | Y | N | 50 | N |
| #13 | 2015 | 75, M | nav | D | - | n-aAC | 3 | Y | Y | Y | Y | N | N | N | 17 | N |
| #14 | 2015 | 75, M | nmv | D | - | - | 3 | Y | Y | N | Y | N | Y | Y | 22 | N |
| #15 | 2017 | 75, M | pav | D | CHF, CD | CLD | 6 | Y | Y | N | Y | N | Y | N | 14 | N |
| #16 | 2017 | 26, F | nmv | D | CHD, MI | - | 0 | Y | Y | N | Y | N | N | N | 27 | N |
| #17 | 2013 | 45, M | nmv | D | VH, MI | n-aAC, HH | 1 | Y | Y | N | Y | N | N | Y | 15 | Y |
| #18 | 2015 | 48, M | nmv | D | MI | - | 0 | Y | Y | Y | N | Y | N | N | 13 | N |
| #19 | 2009 | 51, M | ivd | UN | UN | UN | UN | Y | Y | UN | UN | Y | UN | UN | UN | N |
| #20 | 2010 | 80, M | nav | D | AF, CD, | n-aPC, ARF | 8 | Y | Y | N | N | N | N | N | 17 | N |
| #21 | 2014 | 70, M | nav | D | AF | ITP | 3 | Y | N | N | N | N | Y | Y | 12 | Y |
| #22 | 2014 | 48, M | nav | D | - | - | 0 | Y | Y | N | N | N | N | Y | 2 | N |
| #23 | 2017 | 84, M | pav | D | - | PVD | 5 | Y | N | N | Y | N | Y | N | 11 | N |
| #24 | 2015 | 56, F | nmv | D | NVD | GBD, HYF, FLD | 4 | Y | Y | Y | N | N | Y | N | 11 | N |
| #25 | 2011 | 26, M | nmv | D | CHD, VD, WPWS | - | 0 | Y | Y | N | Y | N | Y | N | 5 | N |
| #26 | 2013 | 76, M | nmv | D | NVD, AF | COPD, | 7 | Y | N | Y | N | N | N | N | 11 | N |
| #27 | 2015 | 17, F | ivd | D | CHD | - | 0 | Y | Y | N | N | N | N | N | 12 | N |
*, according to the modified Duke criteria; †, age-adjusted; ^, days on effective antibiotic therapy prior to valve resection; F, female; ivd, intravascular device; P, possible; CD: coronary disease; AVB, atrioventricular block; PMC, pacemaker carrier; -, not relevant information; N, no; Y, yes; M, male; pav, prosthetic aortic valve; AS, aortic stenosis; MI, mitral insufficiency; HS, heart surgery; UN, unavailable; nav, native aortic valve; D, definite; AI, aortic insufficiency; AF, atrial fibrillation; ARF, acute renal failure; HF, heart failure; DM, dilated cardiomyopathy; LD, liver disease; pmv, prosthetic mitral valve; TI, tricuspid insufficiency; NVD, natural valvular disease; n-a HC, non-active hepatocarcinoma; nmv, native mitral valve; HP, hip prosthesis; CLD, chronic lung disease; GBS, Guillain-Barre syndrome; n-a AC, non-active adenocarcinoma; CHF, congestive heart failure; CHD, congenital heart disease; VH, ventricular hypertrophy; HH, hepatic hemangiomas; n-a PC, non-active prostate carcinoma; ITP, immune thrombocytopenic purpura; PVD, peripheral vascular disease; GBD, Graves–Basedow disease; HYF, hyperferritinemia; FLD, fatty liver disease; VD, valvular disease; WPWS, Wolff–Parkinson–White syndrome; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease.
Comparison between the results obtained by different bioinformatics pipelines.
| Patient ID | Initial Diagnosis | QIIME 1 1 | QIIME 2 2 | Data Refined with BLAST | |||
|---|---|---|---|---|---|---|---|
| #1 |
| 78.7% |
| 99.9% | 99.9% | ||
| #2 |
| 97.5% |
| 98.4% | 99.8% | ||
| #3 |
| 97.1% |
| 99.8% | 99.9% | ||
| #4 | 99.9% | 99.9% | 99.1% | ||||
| #5 | 99.9% | 98.6% | 99.1% | ||||
| #6 |
| 99.8% | 99.3% | 99.6% | |||
| #7 |
| 99.9% | 99.3% | 99.8% | |||
| #8 |
| 99.8% | 99.5% |
| 99.8% | ||
| #9 |
| 99.9% | 99.7% | 99.9% | |||
| #10 |
| 99.9% | 98.8% | 99.9% | |||
| #11 |
| 99.5% | 98.8% |
| 99.5% |
| |
| #12 |
| 99.4% | 99.9% | 99.9% |
| ||
| #13 |
| 99.1% | 99.8% | 99.8% |
| ||
| #14 |
| 99.5% | 99.9% | 99.9% |
| ||
| #15 |
| 98.8% | 99.8% | 99.7% |
| ||
| #16 |
| 99.5% |
| 88.3% | 99.5% |
| |
| #17 |
| 99.9% | 97.8% |
| 99.9% |
| |
| #18 | 99.7% |
| 99.6% | 99.7% |
| ||
| #19 |
| 99.7% | 94.7% | 99.7% |
| ||
| #20 |
| 99.1% | 99.6% | 99.6% |
| ||
| #21 |
| 99.6% |
| 99.9% | 99.6% |
| |
| #22 |
| 99.8% |
| 98.3% |
| 99.8% |
|
| #23 |
| 68.5% | 62.4% | 68.8% |
| ||
| #24 |
| 69.8% | 71.1% |
| 69.5% |
| |
| #25 | No etiology | 95.1% |
| 95.6% | 95.1% |
| |
| #26 |
| 26.9% | 25.6% |
| 26.4% | ||
| #27 |
| 99.8% | 55.5% |
| 99.2% | ||
1, Bioinformatics pipeline based on QIIME (v1.9.1) and Greengenes (as described in Material and Methods); 2, Bioinformatics pipeline based on QIIME2 (qiime2-2020.8) and SILVA (as described in Addendum); subsp., subespecie.